Associations between Comorbid TDP-43, Lewy Body Pathology, and Neuropsychiatric Symptoms in Alzheimer’s Disease

Manuscript Number: 

18-1285R1

Author(s): 
Ece Bayram, Jeffrey Cummings, Guogen Shan

Disclosures

Ece Bayram

  • Nothing to Disclose

Jeffrey Cummings

  • Consulting Fees:
    Dr. Cummings has provided consultation to Acadia, Accera, Actinogen, Alkahest, Allergan, Alzheon, Avanir, Axsome, BiOasis Technologies, Biogen, Bracket, Denali, Diadem, EIP Pharma, Eisai, Forum, Genentech, Green Valley, Grifols, Hisun, Idorsia, Kyowa Kirin, Lilly, Lundbeck, MedAvante, Merck, Otsuka, Pain Therapeutics, Proclara, QR, Resverlogix, Roche, Samus, Sunovion, Suven, Takeda, Teva, Toyama, and United Neuroscience pharmaceutical and assessment companies.
    Equity:
    Dr. Cummings owns stock in ADAMAS, BioAsis, Prana, MedAvante, Neurokos, and QR Pharma.
    Patents/Royalties
    Dr. Cummings owns the copyright of the Neuropsychiatric Inventory (NPI).
    Grants
    • Agency: 
      Avid (In-kind research support)
      Dates: 
      2016-2019
    • Agency: 
      Teva (In-kind research support)
      Dates: 
      2016-2019

Guogen Shan

  • Nothing to Disclose